Table 1

Effect size of controlled trials comparing DMARDs or NSAIDs with placebo or other DMARDs in patients with PsA

DrugFirst authorNtt/NcompMean doseComparatorSJC (*TJC)
(**active JC)
Pain(*patient global assessment)HAQSkinESR (*CRP)Physician global
assessment
MTXScarpa 1216/1910 mg/w IMNSAID+0.33(−0.34 to 1)−0.15 (−0.81 to 0.52)−0.30(−0.97 to 0.37)0.00(−0.67 to 0.67)
Black1110/111–3 mg/kg/d3 inj/10 jPlacebo+++++
Willkens1316/2110 mg/w poPlacebo++++++++++
Spadaro3918/177.5–15 mg/w poCSA 3–5 mg/kg/d0.14(−0.53 to 0.80)*−0.02(−0.68 to 0.65)PASI−0.41(−1.08 to 0.26)0.16(−0.50 to 0.83)++0.59(−0.08 to 1.27)
SSZSalvarani2732/31300 mg–3 g/dTt symptom.+0.42(−0.08 to 0.92)+0.29(−0.20 to 0.79)PASI0.35(−0.15 to 0.85)++0.55(0.05 to 1.05)
Dougados23179/172500 mg–3 g/dPlacebo+0.47(0.03 to 0.90)+0.37(0.16 to 0.58)+0.31(0.10 to 0.52)
Clegg21109/112500 mg–2 g/dPlacebo0.02(−0.24 to 0.28)% surface0.14(−0.12 to 0.40)+0.40(0.14 to 0.67)
Fraser2519/20500 mg–40 mg/kg/dPlacebo++++
Farr2415/15500 mg–2 g/dPlacebo– –0
Combe2253/64500 mg–2 g/dPlacebo*0.17(−0.19 to 0.53)+0.46(0.09 to 0.83)+0.28(−0.09 to 0.65)
Gupta2610/141.5 g–3 g/dPlacebo0.07(−0.74 to 0.89)++0.64(−0.19 to 1.48)+++1.39(0.49 to 2.29)
Salvarani2732/36300 mg–3 g/dCSA 3–5 mg/kg/d0.00(−0.48 to 0.48)- - -−0.98(−1.49 to −0.48)+PASI0.26(−0.22 to 0.73)- -−0.52(−1.0 to −0.03)
CSAFraser3038/342.5–4 mg/kg/dPlacebo0.13(−0.33 to 0.59)+0.26(−0.20 to 0.73)−0.18(−0.64 to 0.28)+PASI0.36(−0.11 to 0.82)−0.12(−0.58 to 0.34)
Salvarani2736/313–5 mg/kg/dTt symptom.+0.45(−0.04 to 0.94)+++1.25(0.72 to 1.77)PASI0.16(−0.32 to 0.64)+++1.14(0.62 to 1.66)
LEFKaltwasser3295/9120 mg/dPlacebo0.14(−0.14 to 0.43)+0.24(−0.05 to 0.53)+PASI0.20(−0.09 to 0.50)+*0.30(0.00 to 0.59)
AURCarette35120/1183–4.5 mg/dPlacebo0.05(−0.23 to 0.34)+0.40(0.11 to 0.69)+*0.43(0.15 to 0.72)% surface0.11(−0.18 to 0.39)
Palit3629/263 mg/dPlacebo– – –+
GoldIMPalit3627/2650 mgPlacebo0++
Palit3627/2950 mgAuranofin 3 mg/d++++
Brückle3721/2150 mg/wAuranofin6 mg/d+
AZALevy673/33 mg/kgPlacebo+++**0.92(−0.76 to 2.60)
Fumaric acidPeeters6813/14120 –720 mgPlacebo0.00(−0.75 to 0.75)++0.56(−0.20 to 1.33)+++% surface0.99(0.19 to 1.79)++0.78(0.00 to 1.57)
NimesulideSarzi-Puttini620/20200 mgPlacebo++0.61(−0.03 to 1.24)++0.70(0.06 to 1.34)
Sarzi-Puttini620/20400 mgPlacebo++0.75(0.11 to 1.39)+0.36(−0.26 to 0.99)
  • The magnitude of the effect size is represented by + (small effect size, 0.2–0.5), ++ (moderate effect size, 0.5–0.8) or +++ (large effect size, ≥0.8). Where calculations were possible, results are presented as effect (95% CI). For indicative results, when SD was estimated from other trials, the effect size is shown only as +, ++ or +++.

  • - -, −−− Negative effect sizes

  • Significant results are in bold type.

  • AUR, auranofin; AZA, azathioprine; CRP, C reactive protein; CSA, cyclosporin A; D, day; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IM, intramuscular; JC, joint count; LEF, leflunomide; MTX, methotrexate; Ntt/Ncomp, number of patients on treatment/number of patients on comparator; NSAID, non-steroidal anti-inflammatory drug; PASI, psoriasis area and severity index; po, orally; PsA, psoriatic arthritis; SJC, swollen joint count; SSZ, sulfasalazine; TJC, tender joint count; w, week.